Four US states that withdrew Medicaid coverage for GLP-1 weight-loss drugs in January 2026 saw prescriptions fall by 84% relative to states that maintained coverage, according to a study published in JAMA on November 16. The finding has direct implications for group benefits brokers advising employers on whether and how to reduce GLP-1 coverage in their own plans.
University of Pittsburgh researchers estimated that between 175,500 and 526,600 fewer Medicaid beneficiaries across California, New Hampshire, Pennsylvania and South Carolina may have filled prescriptions following the coverage changes. Prescriptions fell by 96% in Pennsylvania, 88% in New Hampshire, 75% in California and 61% in South Carolina.
The study covered Medicaid beneficiaries, not commercially insured employees. But the clinical consequence it documents is not programme-specific - it applies to any patient whose GLP-1 coverage ends abruptly, regardless of how that coverage was funded.
“When patients abruptly stop taking these medications, they are at risk of worsening cardiometabolic health related to weight regain,” said lead researcher Dr. Bryant Shuey, an assistant professor of medicine at the University of Pittsburgh.
Researchers could not determine from the data whether patients experienced worse health outcomes or obtained medications through other sources. But the mechanism is established: GLP-1 medications suppress appetite and regulate blood sugar through continuous use. Stopping them without a managed taper or transition typically results in rapid weight regain, which carries associated cardiovascular and metabolic risk.
For a self-funded employer, that risk does not disappear when GLP-1 coverage is removed from the plan. It reappears downstream in cardiac events, type 2 diabetes management and other conditions that drive claims. The study did not quantify those downstream costs, and no study yet has established with certainty whether long-term GLP-1 coverage reduces total medical spend. But a broker advising an employer that is dropping GLP-1 coverage needs to raise the question: how will affected employees transition off the medication, and has the plan accounted for the possibility that some will return as sicker, higher-cost members?
Employer-sponsored plans face the same underlying cost pressure that drove four states to withdraw Medicaid coverage. The 2026 KFF Employer Health Benefits Survey found that 18% of firms with at least 200 workers covered GLP-1 medications primarily for weight loss - and among firms without coverage, 12% had discontinued the benefit within the previous year.
Of employers with at least 5,000 workers that do cover the drugs, 61% reported a significant impact on prescription spending. The commercial pressure is real. But the Medicaid data shows that removing coverage does not make the demand disappear - it shifts the cost and the clinical risk to a different point in the care continuum.
A separate Marsh survey found average employer-sponsored health benefit costs rose 7.3% to $18,777 per employee in 2026, with pharmacy costs rising 9.7% among large employers. The pressure on benefits budgets is not easing.
Some employers are managing GLP-1 costs without eliminating access. Among large employers that continue covering weight-loss GLP-1s, 24% now require participation in a targeted support programme, up from 15% last year, according to Marsh. Others have explored alternative benefit structures such as capped household reimbursements, clinical pathway requirements, and flat monthly copays that provide predictable cost control without abrupt withdrawal.
“These immediate declines corroborate what we saw clinically. Many of my Medicaid-insured patients prescribed GLP-1s for weight management lost coverage,” Shuey said.
Senior researcher Dr. Timothy Anderson, an associate professor of medicine at the University of Pittsburgh, identified manufacturer rebates, multistate purchasing arrangements and federal pricing initiatives as mechanisms that could sustain Medicaid coverage. For employer plans, the equivalent mechanisms are plan design changes that maintain clinical continuity while managing cost - the structured approaches that allow employers to keep coverage accessible without absorbing uncapped pharmacy spend.
For group benefits brokers, the Medicaid data provides a research-backed reference point for a conversation employers increasingly need to have: not just whether to cover GLP-1 medications, but how a decision to remove or restrict coverage should be managed to avoid creating a downstream cost problem the plan was not built to absorb. Employers dropping coverage without a transition plan are, in effect, running the same experiment the four states ran - and the JAMA data shows what that experiment produces.